Efectos de la bromocriptina en pacientes con artritis reumatoide activa / Effects of bromocriptine in patients with active rheumatoid arthritis
Rev. méd. Chile
;
126(1): 33-41, ene. 1998. ilus, tab
Article
in Spanish
| LILACS
| ID: lil-210407
ABSTRACT
Background:
Neuroendocrine factors play an important role in the expression of autoimmune disease. Proclatin (PRL) can induce T-cell proliferation and macrophage activation. Elevated PRL levels have been described in patients with rheumatoid arthritis and (RA). Aim andMethods:
We studiend immunological and clinical effects of PRL suppression in 9 RA patients with active disease, treated for 3 months with bromocriptiner (BRC), an inihibitor of PRL secretion.Results:
BRC induced a significant depression of the peripheral blood mononuclear cells response to antigen (p=0.008) and mitogen (p=0.008) which was significantly correlated with improvements in the HAQ disability index (r=0.68; p=0.04) and grip strength (r=0.7; p=0.02). Also, the in-vitro production of IL-2, nitric oxide and poliamines -that are critical for the proliferative response of lymphoid cells- decreased significantly. The group experienced significant improvement of grip strength (p=0.028) and the HAQ disability index (p=0.025), whereas 4 individuals archieved clinical improvement according to the American College of Rheumatology preliminary definition. We conclude that BRC treatment induces a significant depression of in-vitro immune function in RA patients and these changes are related to parameters of disease activity. The effects of BRC on immune function and disease activity in RA patients warrant further investigation
Search on Google
Index:
LILACS (Americas)
Main subject:
Arthritis, Rheumatoid
/
Bromocriptine
Limits:
Female
/
Humans
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
1998
Type:
Article
/
Project document
Similar
MEDLINE
...
LILACS
LIS